Breast, Colorectal, Lung, Prostate, and Cervical Cancer Screening Prevalence in a Large Commercial and Medicare Advantage Plan, 2008–2020

Our colleagues recently published a large-scale analysis to comprehensively assess breast, colorectal, cervical, lung, and prostate cancer screening rates and trends in the US over time among individuals for whom screening is recommended by the United States Preventive Services Task Force (USPSTF). Cancer screening rates remain suboptimal and efforts to increase uptake seemed stalled. Future research with a diverse set of methods to screen and ultimately improve outcomes among patients with cancer are essential if current approaches to improve cancer screening rates can not be achieved.

Kim A, Gitlin M, Fadli E, et al. Breast, Colorectal, Lung, Prostate, and Cervical Cancer Screening Prevalence in a Large Commercial and Medicare Advantage Plan, 2008–2020. Prev Med Rep. 2022;30:102046. https://www.sciencedirect.com/science/article/pii/S2211335522003539